The situation that is holding the share price down hasn't changes in any material way. <br /> <br /> The MOA is still unproven in many peoples eyes. The paradigm is still novel and unaccepted by the general biotech investor. The company doesn't have an approved drug, has not applied for an NDA yet. And the relatively low volume does make the share price vulnerable to manipulation by the usual market forces. The only completed placebo controlled trial has not yet released a full report for detailed analysis. <br /> <br /> Trial results are all that matter.... still.